wire - news in brief
Life Sciences - Jun 25
Environment - Jun 25
Researchers at EPFL have precisely quantified convection heat transfer in rail tunnels. Using the new model, they estimated how much energy Lausanne could save by fitting the future M3 metro line with a geothermal heat-recovery system, in what would be a world first.
Pharmacology - Jun 24
Following a stroke, antibodies that inhibit the signaling molecule Nogo-A can help repair blood vessels in the affected brain regions.
Category
Results 1 - 50 of 326.
Grassland Researchers Meet in Zurich
Switzerland is a grassland. The climate and soil provide ideal conditions for grass production, and thus for sustainable milk and meat production, whilst natural conditions are often unfavourable for arable farming. However, grass production too is facing new challenges. Despite extreme weather such as drought, the agricultural sector aims to produce top-quality forage, so that concentrate use can be reduced as much as possible.
Switzerland is a grassland. The climate and soil provide ideal conditions for grass production, and thus for sustainable milk and meat production, whilst natural conditions are often unfavourable for arable farming. However, grass production too is facing new challenges. Despite extreme weather such as drought, the agricultural sector aims to produce top-quality forage, so that concentrate use can be reduced as much as possible.
Sports scientists from the University of Basel found that providing telephone-based coaching over the phone is an effective method for getting people in Switzerland to adopt a physically active lifestyle. Physical activity is a good way to minimize various health risks - regardless of gender, age and fitness level.
The Latin version of Théodore de Bry's Voyages is available on line in its entirety for the first time.
Japan becomes the first country to approve Roche’s personalised medicine Rozlytrek
First tumour-agnostic medicine approved in Japan for adult and paediatric patients with NTRK fusion-positive advanced recurrent solid tumours Approval supported by the data mainly from the pivotal Ph
First tumour-agnostic medicine approved in Japan for adult and paediatric patients with NTRK fusion-positive advanced recurrent solid tumours Approval supported by the data mainly from the pivotal Ph
EPFL's Laboratory for Ultrafast Microscopy and Electron Scattering has received a grant from Google to use shaped electron beams in the cutting-edge field of Nuclear Excitation by Electron Capture (NEEC). Dr Fabrizio Carbone's Laboratory for Ultrafast Microscopy and Electron Scattering (LUMES) today announced that Google has funded a 4-year research project in the lab.
New analysis of Novartis data confirms that Cosentyx demonstrates durable comprehensive treatment across psoriatic disease
For the first time efficacy and safety data from dedicated phase III trials are analyzed together in one abstract, backing Cosentyx as comprehensive treatment across multiple manifestations of psoria
For the first time efficacy and safety data from dedicated phase III trials are analyzed together in one abstract, backing Cosentyx as comprehensive treatment across multiple manifestations of psoria
New Sandoz biosimilar adalimumab data confirms switching from reference biologic has no impact on safety or efficacy
Data show switching to Hyrimoz (biosimilar adalimumab) from the reference medicine provides sustained efficacy with no new safety concerns in patients with moderate-to-severe rheumatoid arthritis A
Data show switching to Hyrimoz (biosimilar adalimumab) from the reference medicine provides sustained efficacy with no new safety concerns in patients with moderate-to-severe rheumatoid arthritis A
Novartis continues to innovate in CML with long-term treatment-free remission results following Tasigna use and promising combination data with investigational compound asciminib (ABL001)
Results from two Phase II trials, ENESTfreedom and ENESTop, support and extend previous findings of long-term durability of molecular response after stopping Tasigna, reducing time on drug for many C
Results from two Phase II trials, ENESTfreedom and ENESTop, support and extend previous findings of long-term durability of molecular response after stopping Tasigna, reducing time on drug for many C
Survey shows high levels of employee satisfaction at the University of Bern
On the whole, employees at the University of Bern are very satisfied or mostly satisfied with their work and, in general, have a high level of commitment. This is according to the results of the 2019 staff survey. One aspect which staff particularly enjoy is the diverse nature of their work. An up-to-date analysis of wage equality also yielded positive results: at the University of Bern, men and woman earn the same amount for work which is of equal value.
On the whole, employees at the University of Bern are very satisfied or mostly satisfied with their work and, in general, have a high level of commitment. This is according to the results of the 2019 staff survey. One aspect which staff particularly enjoy is the diverse nature of their work. An up-to-date analysis of wage equality also yielded positive results: at the University of Bern, men and woman earn the same amount for work which is of equal value.
The Fabula team at Twitter UK office. Left to right: Michael Bronstein, Fabrizio Frasca, Emanuele Rossi, Davide Eynard, Federico Monti, Damon Mannion (image: Stacey Conti).
Novartis Cosentyx first to show efficacy in all key manifestations of psoriatic arthritis
First-of-its-kind data shows efficacy and safety of a biologic in the management of axial manifestations of psoriatic arthritis (PsA), which affect up to an estimated 35 million people worldwide 66
First-of-its-kind data shows efficacy and safety of a biologic in the management of axial manifestations of psoriatic arthritis (PsA), which affect up to an estimated 35 million people worldwide 66
Cosentyx provides long-lasting inhibition of radiographic progression in psoriatic arthritis, new Novartis data show
Almost 90% of patients had no radiographic progression of psoriatic arthritis (PsA) at 2 years with Cosentyx (secukinumab) 300mg Data at 2 years demonstrate over 50% of adults with active PsA achie
Almost 90% of patients had no radiographic progression of psoriatic arthritis (PsA) at 2 years with Cosentyx (secukinumab) 300mg Data at 2 years demonstrate over 50% of adults with active PsA achie
In its first two years, the BRIDGE funding programme has financed 81 projects at the interface of basic science and science-based innovation.
FDA grants Roche’s Polivy accelerated approval for people with previously treated aggressive lymphoma
New targeted medicine shown to improve clinical outcomes in people with relapsed or refractory diffuse large B-cell lymphoma compared to a commonly used regimen First-in-class antibody-drug conjugate that specifically targets CD79b, a protein expressed in the majority of B-cells Ninth indication with Breakthrough Therapy Designation in Roche's haematology portfolio to receive FDA approval Roche today announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Polivy?
New targeted medicine shown to improve clinical outcomes in people with relapsed or refractory diffuse large B-cell lymphoma compared to a commonly used regimen First-in-class antibody-drug conjugate that specifically targets CD79b, a protein expressed in the majority of B-cells Ninth indication with Breakthrough Therapy Designation in Roche's haematology portfolio to receive FDA approval Roche today announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Polivy?
At the end of June, the University of Bern is holding a diverse science festival to mark the occasion of the 50th anniversary of the moon landing: a multimedia show on Bundesplatz will display milest
For 13 years, the "bilding" foundation has been committed to promoting the next generation of engineers in the construction industry, which also includes the Building Award for remarkable and innovative engineering achievements in construction.
Advanced Accelerator Applications Receives Positive CHMP Opinion for LysaKare
Advanced Accelerator Applications Receives Positive CHMP Opinion for LysaKare for Reduction of Kidney Exposure to Radiation During Peptide Receptor Radionuclide Therapy with Lutetium ( 177 Lu) Oxodot
Advanced Accelerator Applications Receives Positive CHMP Opinion for LysaKare for Reduction of Kidney Exposure to Radiation During Peptide Receptor Radionuclide Therapy with Lutetium ( 177 Lu) Oxodot
EPFL biophysicists have taken a systematic look into how bacterial biofilms are affected by fluid flow. The findings can give us clues about the physical rules guiding biofilm architecture, but also about the social dynamics that shape evolution. Although we tend to think of them as solitary sojourners of the world, bacteria are actually very social organisms.
UNEP/GRID-Geneva, the universities of Geneva and Zurich and the Swiss Federal Institute for Forest, Snow and Landscape Research join forces for the continuous monitoring of Switzerland from space using the Swiss Data Cube.
Long-term survival benefit shown for metastatic melanoma patients treated with Novartis Tafinlar + Mekinist
Five-year Tafinlar + Mekinist survival data presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting and published simultaneously in The New England Journal of Medicine Results are from the largest dataset and longest follow-up of more than 500 patients with BRAF-mutated metastatic melanoma, a genetic mutation common for this aggressive skin cancer Additional Novartis melanoma research presented at ASCO includes effi
Five-year Tafinlar + Mekinist survival data presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting and published simultaneously in The New England Journal of Medicine Results are from the largest dataset and longest follow-up of more than 500 patients with BRAF-mutated metastatic melanoma, a genetic mutation common for this aggressive skin cancer Additional Novartis melanoma research presented at ASCO includes effi
Pivotal phase III CLL14 results for Venclexta/Venclyxto in combination with Gazyva/Gazyvaro for chronic lymphocytic leukaemia presented at ASCO 2019 and published in the New England Journal of Medicine
Venclexta/Venclyxto plus Gazyva/Gazyvaro showed improvements across multiple efficacy measures compared to Gazyva/Gazyvaro plus chlorambucil, including progression-free survival and deep remissions a
Venclexta/Venclyxto plus Gazyva/Gazyvaro showed improvements across multiple efficacy measures compared to Gazyva/Gazyvaro plus chlorambucil, including progression-free survival and deep remissions a
On May 28, the EPFL School of Computer and Communication Sciences (IC) and Science Outreach Department (SPS) organized the final of the first Swiss edition of the Alkindi Competition, where more than 40 secondary school students from across the country put their code-cracking skills to the test.
Researchers from UNIGE have shown that children lose their motivation to participate in physical activities in PE classes at school from the age of nine.
The bigger the brain, the more intelligent a mammalian species is. Developing a large brain, though, requires a huge energy input.
Roche presents data from across its breast cancer portfolio at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
Roche data from 17 breast cancer abstracts presented at this year's meeting An overall survival improvement was observed with Tecentriq and nab-paclitaxel in PD-L1-positive metastatic triple-negative
Roche data from 17 breast cancer abstracts presented at this year's meeting An overall survival improvement was observed with Tecentriq and nab-paclitaxel in PD-L1-positive metastatic triple-negative
Xolair (omalizumab) significantly reduced nasal polyps and congestion symptoms in adults with chronic rhinosinusitis with nasal polyps in two phase III studies
In the phase III POLYP 1 and POLYP 2 studies, omalizumab met both co-primary endpoints and key secondary endpoints in adults with chronic rhinosinusitis with nasal polyps (CRSwNP) with inadequate res
In the phase III POLYP 1 and POLYP 2 studies, omalizumab met both co-primary endpoints and key secondary endpoints in adults with chronic rhinosinusitis with nasal polyps (CRSwNP) with inadequate res
Novartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investigational Data and Novel Canakinumab Clinical Trials
Primary analysis of investigational capmatinib (INC280) in the GEOMETRY mono-1 study demonstrates promising efficacy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
Primary analysis of investigational capmatinib (INC280) in the GEOMETRY mono-1 study demonstrates promising efficacy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
Roche’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer shows positive data in those with liver metastases
Data will be presented at the American Society of Clinical Oncology (ASCO) annual meeting on 2 June 2019 Roche today announced positive additional results of a prespecified exploratory analysis from
Data will be presented at the American Society of Clinical Oncology (ASCO) annual meeting on 2 June 2019 Roche today announced positive additional results of a prespecified exploratory analysis from
Novartis Kisqali significantly extends life in women with HR+/HER2- advanced breast cancer in MONALEESA-7 trial
Kisqali is the only CDK4/6 inhibitor to show superior overall survival in advanced breast cancer (HR=0.712; p=0.00973) After a median of 42 months follow-up, the survival rate was 70&pe
Kisqali is the only CDK4/6 inhibitor to show superior overall survival in advanced breast cancer (HR=0.712; p=0.00973) After a median of 42 months follow-up, the survival rate was 70&pe
Researchers at EPFL have developed a machine that turns seawater into drinking water in a more environmentally friendly and economical way than existing systems.
Roche and GE Healthcare launch NAVIFY Tumor Board with medical imaging capabilities to enable more personalised treatment decisions in cancer care
Radiologists can now upload their patient records to the same dashboard as patient files from other disciplines First collaboration product enables tumour boards to have a more comprehensive view of
Radiologists can now upload their patient records to the same dashboard as patient files from other disciplines First collaboration product enables tumour boards to have a more comprehensive view of
"Science Wire" gives access to latest science news from universities, research centers and R&D companies.Add this page to your bookmarks
